Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Deep versus moderate neuromuscular blockade for CT-guided liver tumor radiofrequency ablation
ACTRN12615000838516Phase 3Recruiting
- Sponsor
- Universiti Malaya
- Start
- Jun 2015
- Modality
- Small Molecules, Peptides
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial of rocuronium and atracurium in hepatic neoplasm, hepatocellular carcinoma (HCC) and hepatic metastasis, sponsored by Universiti Malaya. Primary endpoints: Mean liver excursion during procedure and Ease of performing radiofrequency ablation. Started Jun 2015; status: recruiting.
02
Drugs
rocuroniumatracurium
03
Conditions
hepatic neoplasmhepatocellular carcinoma (HCC)hepatic metastasis
Beyond the preview
Go deeper on ACTRN12615000838516.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ACTRN12615000838516.